Abstract: There is provided pharmaceutical compositions for the treatment of e.g. opioid dependency comprising microparticles of a pharmacologically-effective amount of buprenorphine, or a pharmaceutically-acceptable salt thereof, in associative admixture with particles comprising a weak acid, or particles comprising weakly-acidic buffer forming materials. The composition may further comprise a disintegrant and/or particles of a pharmacologically-effective amount of naloxone, or a pharmaceutically-acceptable salt thereof. The compositions are useful in the treatment of opioid dependency/addiction and/or pain.

Abstract: The invention pertains to a method of relieving pain by administering a controlled release pharmaceutical tablet containing oxymorphone which produces a mean minimum blood plasma level 12 to 24 hours after dosing, as well as the tablet producing the sustained pain relief.

Abstract: Disclosed herein are compounds, their pharmaceutical salts, and pharmaceutical compositions that selectively activate the inositol-requiring enzyme 1 (IRE1)/X-box binding protein 1 (XBP1s) signaling pathway of the unfolded protein response (UPR), but that do not target the IRE1 kinase domain.

Abstract: The invention relates to particular substituted deuterated heterocycle fused gamma-carbolines, their prodrugs, in free, solid, pharmaceutically acceptable salt and/or substantially pure form as described herein, pharmaceutical compositions thereof, and methods of use in the treatment of diseases involving 5-HT2A receptor, serotonin transporter (SERT) and/or pathways involving dopamine D1/D2 receptor signaling systems, and/or the treatment of residual symptoms.

Abstract: The application relates to methods of curing retroviral infections, i.e. ensuring remission of retroviral infections, more particularly HIV infections, by administering a compound which is capable of binding to the LEDGF/p75 binding pocket of HIV-integrase and inhibiting LEDGF/p75-IN protein-protein interaction. The application further relates to the use of LEDGINs in retroviral gene therapy.

Abstract: Provided is a medicament or a method for treating or preventing a corneal endothelial condition, disorder or disease due to a transforming growth factor-? (TGF-?) signal in corneal endothelial cells using a p38 MAP kinase inhibitor (in particular AKP-001), such as a pyrimidinyl isoxazole derivative or a pyridyl isoxazole derivative. In a preferred embodiment, the corneal endothelial condition, disorder or disease due to the TGF-? signal is Fuchs' corneal endothelial dystrophy.

Abstract: Solid pharmaceutical dosage forms comprising (S)-ethyl 2-amino-3-(4-(2-amino-6-((R)-1-(4-chloro-2-(3-methyl-1H-pyrazol-1-yl)phenyl)-2,2,2-trifluoroethoxy)pyrimidin-4-yl)phenyl)propanoate (telotristat) are disclosed, as well as methods of making them and compositions useful in their manufacture.

Abstract: The present invention aims to provide a pharmaceutical drug that contains a compound having an excellent therapeutic effect on inflammatory bowel disease. A therapeutic agent for inflammatory bowel disease, containing as an active ingredient a compound represented by formula (I), wherein R1 represents a hydroxy C1-C6 alkyl group, a C2-C7 alkanoyl group, a C2-C7 alkanoyl C1-C6 alkyl group, a (C1-C6 alkoxy) carbonyl group, a (C1-C6 alkoxy) carbonyl C1-C6 alkyl group, a carboxy group or a carboxy C1-C6 alkyl group, or a pharmacologically acceptable salt thereof.

Abstract: The invention relates to the field of tumor treatment, in particular to melanoma tumor treatment. In particular it relates to the use of CD36 antagonists for use in tumor treatment, in particular for use in reducing tumor cell heterogeneity during minimal residual disease (MRD), and thus for use in treating MRD. Even more in particular, the invention relates to the use of CD36 antagonists in combination with clinically established treatments such as treatment with a combination of BRAF and MEK inhibitors, and optionally other anticancer agents.

Abstract: Methods for treating respiratory and gastrointestinal diseases mediated by a P2X3 and/or a P2X2/3 receptor antagonist, the methods comprising administering to a subject in need thereof an effective amount of a compound of formula (I): or a pharmaceutically acceptable salt thereof, wherein D, X, Y, R1, R2, R3, R4, R5, R6, R7 and R8 are as defined herein.

Abstract: A pharmaceutical composition comprises: a) 5 wt % to 95 wt % of a HCl salt of Compound (1).xH2O by the weight of the pharmaceutical composition, wherein x is from 0 to 3; and b) 5 wt % to 95 wt % of a filler by the weight of the pharmaceutical composition. Another pharmaceutical composition comprises: a) 1 mg/mL to 20 mg/mL of Compound (1) in water; and b) 0.01 M to 0.1 M of a pharmaceutically acceptable pH modifier. A method of preparing a pharmaceutical composition, comprising providing a mixture of Compound (1) that includes the HCl salt of Compound (1).xH2O and the filler. Another method of preparing a pharmaceutical composition comprises mixing the HCl salt of Compound (1).xH2O and the pH modifier to form 1 mg/mL to 20 mg/mL of Compound (1) in water. Methods of reducing the amount of influenza viruses, inhibiting the replication of influenza viruses, and treating influenza each independently employ such pharmaceutical compositions.

Abstract: In certain embodiments the present invention involves methods of killing tumor cells that comprise an oncogenic PDGFR mutation, and methods of treating subjects having tumors that comprise such tumor cells. In some embodiments such methods involve using PI3K inhibitors, or a combination of a PI3K inhibitor and an mTOR inhibitor, or a dual PI3K/mTOR inhibitor. The present invention also provides methods for determining whether a subject is a candidate for treatment, methods for evaluating the efficacy of treatment, and other methods, compositions, model systems, and assays.

Abstract: The present application provides methods of treating a disease, such as Pompe disease, in a subject, comprising detecting an erythropoiesis biomarker in a sample of the subject after administration of methotrexate and a therapeutic agent to the subject, and administering further treatment with or without concurrently administering additional immune tolerance induction or immunosuppression therapy based on the level of the erythropoiesis biomarker. Further provided by the present application are methods and kits for assessing the level of immune tolerance to a therapeutic agent in a subject based on detection of an erythropoiesis biomarker after administration of methotrexate and the therapeutic agent to the subject.

Abstract: The disclosure provides a method of treating a an INI1-deficient tumor in a subject in need thereof comprising administering to the subject a therapeutically-effective amount of an enhancer of a zeste homolog 2 (EZH2) inhibitor. In a preferred embodiment of this method, the subject is pediatric and the EZH2 inhibitor is Tazemetostat.

Abstract: Provided herein are nanoparticle compositions comprising modulators of the Bcl-2 family proteins, and pharmaceutically acceptable carriers.

Abstract: This invention relates to agents that are inhibitors or activators of variant forms of endogenous proteins and novel methods of identifying such variants. Of particular interest are inhibitors and activators of endogenous protein variants, encoded by genes which have mutated, which variants often arise or are at least first identified as having arisen following exposure to a chemical agent which is known to be an inhibitor or activator of the corresponding unmutated endogenous protein.

Abstract: The present disclosure relates to compounds of Formula I, its stereoisomers, pharmaceutically acceptable salts, complexes, hydrates, solvates, tautomers, polymorphs, racemic mixtures, optically active forms and pharmaceutically active derivative thereof and pharmaceutical compositions containing them as the active ingredient which can be used as medicaments. The aforementioned substances can also be used in the manufacture of medicaments for treatment, prevention, or suppression of diseases, and conditions mediated by microbes. The present disclosure also relates to the synthesis and characterization of aforementioned substances.

Abstract: The present invention comprises a composition and method treating eye diseases using a composition having a therapeutically effective amount of a progestagen and a pharmaceutically acceptable carrier, wherein the composition is applied to the palpebral part of the eye and/or ocular surface.

Abstract: This invention relates the use of cortisol blockers (glucocorticoid receptor [GR] antagonists) for the treating or preventing treatment resistant prostate cancer, treating or preventing neoplasia, and treating or preventing infection related to acute or chronic injury or disease.

Abstract: Liquid formulations of Abiraterone intended for oral administration are provided. Also provided are suspension and emulsion formulations of Abiraterone and processes of preparing such formulations. Further, embodiments of the invention relates to Nanoemulsion formulations of Abiraterone including Abiraterone, oil phase, aqueous phase, one or more emulsifying agents and optionally other pharmaceutical excipients, wherein the concentration of excipients are optimized for better stability.

Abstract: Fragrance compositions comprising one or more fragrance compounds for use in increasing the duration of sleep and/or improving quality of sleep in a subject is disclosed. Fragrance compositions comprising one or more fragrance compounds for use in increasing the quality of sleep in a subject (i.e., an increase in the time the subject is asleep during the night, a decrease in the time the subject is awake during the night, an increase in the time the subject experiences REM sleep, an increase in the time the subject experiences deep sleep, an increase in the time the subject experiences light sleep; and an increase in overall sleep efficiency) is disclosed. The composition can be incorporated into various consumer end products.

Abstract: The present invention is in the field of a use of a bisphosphonate acid, specifically a salt thereof, or analogue thereof, or combinations thereof, in a medicament for naturally occurring diseases/disorders in a mammal, the mammal being selected from the orders of Perissodactyla, such as the family of Equidae (horses), (Cet)Artiodactyla, such as the family of Bovidae (cattle), and Carnivora, such as the families of Canidae (e.g. dogs) and Felidae (e.g. cats).

Abstract: Provided in the present invention is the use of a mevalonic acid pathway inhibitor in the preparation of a drug for treating and/or preventing tumours, inducing immunogenic death of tumour cells, inducing immune responses and activating T cells or DC cells to directly promote host immunity. Also provided in the present invention is a pharmaceutical composition comprising the mevalonic acid pathway inhibitor and an antitumour drug (for example, an immune checkpoint inhibitor and any drug that can lead to new antigen production) and a combination of the mevalonic acid pathway inhibitor and an antitumour drug (for example, an immune checkpoint inhibitor and any drug that can lead to new antigen production) and/or the radiotherapy.

Abstract: The present invention relates to a method for treating dermal inflammation and dermal diseases by local or systemic delivery, in a subject in need of such treatment, which comprises administering a pharmaceutical composition comprising a therapeutically effective amount of at least one agonist of Formyl peptide receptor 2 (FPR2).

Abstract: This invention relates to nutritional compositions comprising at least one N-acetylated oligosaccharide for use in the promotion of the development and/or of the growth of the intestinal muscles, in the promotion of contractile capacity and/or the motility in the intestine, in the promotion of enteral feeding tolerance and in prevention and/or treatment of small intestinal bacterial overgrowth (SIBO) in an infant, a young child or, when the composition is a growing-up milk, in a child.

Abstract: The application relates to synthetic compositions and methods for preventing or reducing nociception and/or nociceptive sensitivity in a non-infant human The human is administered a composition comprising 6?-sialyllactose (6?-SL) and/or lacto-N-tetraose (LNT).

Abstract: The present invention relates to a pharmaceutical composition, a health functional food, and a feed composition for the prevention, improvement, or treatment of non-alcoholic liver disease or insulin resistance comprising ginsenoside F2. The pharmaceutical composition according to the present invention comprising ginsenoside F2 can inhibit the adipogenesis and lipid accumulation in the liver, improve insulin sensitivity, inhibit the expression of inflammatory cytokines such as TNF-?, IL-?, and IL-6 in the Kupffer cell, inhibit the expression of endocannabinoid synthase, thus capable of effectively preventing or treating non-alcoholic liver disease or insulin resistance.

Abstract: The present invention alleviates a sign or symptom of an aggregation disease or disorder by administering an aqueous formulation comprising trehalose.

Abstract: A particulate substance mixture, preferably for use in the prophylaxis and/or treatment of a respiratory disorder includes a mucolytic substance and amorphous silicon dioxide. The mixture may also have the following characteristics: the amorphous silicon dioxide is hydrophilic silicon dioxide, the amorphous silicon dioxide has a mean particle diameter ?20 ?m, and an amount of the amorphous silicon dioxide is 0.1% by weight to 10% by weight, based on the total weight of the particulate substance mixture.

Abstract: The present invention provides liposome compositions containing sparingly soluble drugs that are used to treat life-threatening diseases. A preferred method of encapsulating a drug inside a liposome is by remote or active loading. Remote loading of a drug into liposomes containing a transmembrane electrochemical gradient is initiated by co-mixing a liposome suspension with a solution of drug, whereby the neutral form of the compound freely enters the liposome and becomes electrostatically charged thereby preventing the reverse transfer out of the liposome. There is a continuous build-up of compound within the liposome interior until the electrochemical gradient is dissipated or all the drug is encapsulated in the liposome. However, this process as described in the literature has been limited to drugs that are freely soluble in aqueous solution or solubilized as a water-soluble complex. This invention describes compositions and methods for remote loading drugs with low water solubility (<2 mg/mL).

Abstract: A method of treating a central nervous system disease, the method including administering an agent including a therapeutically effective amount of vitamin B12 to a patient with a central nervous system disease to treat the central nervous system disease. This disclosure also relates to a method of promoting M2 macrophage/microglia induction, inhibiting M1 macrophage/microglia induction, and/or reducing the ratio of M1 macrophage/microglia to M2 macrophage/microglia in a patient in need thereof, the method including administering an agent including a therapeutically effective amount of vitamin B12 to the patient to promote M2 macrophage/microglia induction, inhibit M1 macrophage/microglia induction, and/or reduce the ratio of M1 macrophage/microglia to M2 macrophage/microglia. This disclosure also relates to a pharmaceutical product including vitamin B12.

Abstract: The present invention relates generally to methods and compositions for gene therapy and immunotherapy that activate gamma delta T-cells, and in particular, can be used in the treatment of various cancers and infectious diseases.

Abstract: The present invention relates to a composition for relieving a hangover or a composition for preventing, alleviating or treating alcoholic liver disease, comprising a ?-glucan as an active ingredient

Abstract: The present disclosure provides, among other things, improved compositions and methods for treating muscular dystrophy. For example, the disclosure provides methods for treating Duchenne muscular dystrophy patients having a mutation in the DMD gene that is amenable to exon 51 skipping by administering an effective amount of eteplirsen.

Abstract: The invention relates to the use of an adsorbent to reduce or suppress the pathogenicity or virulence of Clostridium bacteria in vitro, ex vivo or in vivo. The invention may be used in any mammal or environment, and is particularly effective to suppress the pathogenicity or virulence of Clostridium difficile.

Abstract: Methods and compositions for reducing fibrosis and cirrhosis are provided in which an effective dose of an admixture of a polysaccharide compound and, for example, a compound selected from the group consisting of antibodies specific to intracellular or cell-surface: (i) beta-PDGF receptors; (ii) synaptophysin; (iii) zvegf3; (iv) CCR1 receptors; (v) connective tissue growth factor; (vi) alpha 1-smooth muscle actin; (vii) matrix metalloproteinases MMP 2 and MMP9; (viii) matrix metalloproteinase inhibitors TIMP1 and TMP2; (ix) integrins; (x) TFG-?1; (xi) endothelin receptor antagonists; and (xii) collagen synthesis and degradation modulating compounds; (xiii) actin synthesis and degradation modulating compounds; and (xiv) tyrosine kinases is administered to an animal in order to treat fibrosis.

Abstract: Acetylated polysaccharides and methods of making and using them are provided. One method of making acetylated polysaccharides includes providing polysaccharides, purifying the polysaccharides to 1-90% purity by weight, providing an acetylation agent, providing a catalyst, mixing the acetylation agent and catalyst with the polysaccharides, thereby manufacturing acetylated polysaccharides, and purifying the acetylated polysaccharides.

Abstract: Ligand Drug Conjugates of hydrophobically-modified auristatin F compounds that exhibit cytotoxic activities towards targeted cells, including abnormal cells such as cancer cells, that are MDR+ while also exhibiting bystander activities towards nearby cells having lower expression of the moeity targeted by the Conjugate.

Abstract: A method of treating infection and/or inflammation in a subject includes steps of providing a polyester biomaterial comprising diol monomers and at least first carboxylate monomers, wherein the first carboxylate monomers are itaconate; and administering the polyester biomaterial to the subject. The polyester biomaterial can be in the form of a biomimetic, and characterized by hydrolytic degradability. The polyester biomaterial may further include second carboxylate monomers. The biomaterial can be poly(itaconate-co-citrate-co-octanediol).

Abstract: The present invention relates to methods and compositions for preventing, reducing or eradicating toxicity caused by acetaminophen (APAP). Specifically, the toxicity is nephrotoxicity and/or hepatotoxicity.

Abstract: The present technology provides regenerative treatment methods and apparatus to promote regeneration of target biological tissue. Regenerative treatments include the subcutaneous and cutaneous application of carbon dioxide. Regenerative treatment methods include an initial treatment phase and a maintenance treatment phase. Regenerative treatment apparatus include effervescent mineral compositions for cutaneous application of carbon dioxide.

Abstract: Ayurvedic encapsulated gold nanoparticles, methods of fabrication and methods of treatment are provided. A method of fabrication includes mixing dried gooseberry product or mango peel product or phytochemical existent therein, into a liquid medium to form a reducing agent solution. Gold salts are mixed into the reducing agent solution. Reaction of the gold salts proceeds, in the absence of any other reducing agent, to form a nanoparticle solution of stabilized, biocompatible Ayurvedic encapsulated gold nanoparticles. An Ayurvedic medicine consists of a non-radioactive gold nanoparticle encapsulated with phytochemical existent in mango peal or gooseberry in a capsule with curcumin extract and gum Arabic.

Abstract: The description provides compositions and methods of using a pyrophosphate analog, in which the bridging oxygen is replaced with an imido group (PNP) to increase the rate of the reverse polymerase reaction.

Abstract: A method for stimulating the synthesis of nasal nitric oxide and nasal and lung surfactants to inhibit the docking and adhesion of viruses to cellular receptors, including ACE2, to reduce viral replication, duration, spread and severity of infections, and also to inhibit lung fibrosis, increase the synthesis of serotonin to reduce coughing and mouth breathing, reduce the cytokine storm produced by LI-6 caused by viruses such as COVID-19 and flu in patients susceptible to these infections, including patients with hypoxemia, asthma, chronic obstructive pulmonary disease, cystic fibrosis, diabetics, interstitial lung disease, pulmonary fibrosis, allergic rhinitis, sinusitis, smokers, sleep apnea and lung cancer, which includes: contacting mammalian cells with a therapeutically effective amount of a composition, said composition including the following constituents: sodium pyruvate; a phosphate; a salt of calcium; and a salt of magnesium.

Abstract: Methods and compositions relating to isolated mitochondria are disclosed. For example, cells, tissues, or organs can be treated with isolated mitochondria, such as porcine mitochondria, to improve mitochondrial function in the cell, tissue, or organ. The improvements to mitochondrial function include increased oxygen consumption and increased ATP synthesis. Such methods and compositions are useful for cell therapy; organ and tissue transplantation; organ and tissue engineering; and cold storage or shipment of harvested organs, tissues, and cells.

Abstract: Cytokine induced memory like (CIML) NK cells with enhanced cytotoxicity are presented. Most typically, the CIML NK cells are derived from a mononuclear cell fraction of peripheral blood or cord blood. In further contemplated aspects, the CIML NK cells are expanded and induced in a contained and automated production environment that substantially reduces operational complexity and production cost.

Abstract: The present invention is relative to an isolated nucleic acid molecule encoding a chimeric antigen receptor (CAR), wherein the CAR comprises an antibody or antibody fragment which includes a anti-IL-1RAP binding domain, polypeptides encoded by this nucleic acid molecule, isolated chimeric antigen receptor (CAR) molecule comprising such an antibody or antibody fragment, a vector comprising a nucleic acid molecule encoding a CAR, as well as a T cell comprising this vector. The present invention is also relative to the use of this T cell (autologous or allogeneic) expressing a CAR molecule to treat a proliferative disease in a mammal.

Abstract: Provided herein are methods of treating a hematological disorder, a solid tumor, or an infectious disease in a subject in need thereof using natural killer cells in combination with a second agent, or using natural killer cells with genetic modifications for target specificity and/or homing specificity.

Abstract: Provided herein are methods for treating a patient with HIV, cancer, a viral infection, or a bacterial infection, comprising administering an effective amount of activated lymphocytic cellular compositions. Related compositions, kits, and methods for modulating the immune system using the activated lymphocytic cellular compositions are also provided.

Abstract: Cell therapy compositions comprising engineered human regulatory T cells (eTregs) characterized by ectopic overexpression of FOXP3 and Helios protein, produced via introduction of separate nucleic acid constructs respectively encoding FOXP3 and Helios (FOXP3+Helios+eTregs). Cell therapy compositions comprising mixed populations of CD4+ and CD8+ Treg cells each with ectopic overexpression of FOXP3 and Helios. Methods of making and use the same for therapies involving inflammation and/or a disorder of the immune system.